Trending...
- Maryland Agriculture Secretary Kevin Atticks to Lead Regional Ag Association as Incoming President
- PUBLIC NOTICE Maryland Agencies to Treat Potomac River for Black Fly Control on June 27
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
GAITHERSBURG, Md., April 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the Goldman Sachs Recovery Inoculated: The Current Outlook for COVID-19 Vaccines, Treatments, Testing and the Economy virtual conference. Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
More on Marylandian
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
[email protected]
Solebury Trout
Jennifer Porcelli | 646-378-2962
[email protected]
Media
Laura Keenan | 410-419-5755
Amy Speak | 617-420-2461
[email protected]
SOURCE Novavax, Inc.
Related Links
http://www.novavax.com
Fireside chat details: | |||
Date: | Tuesday, April 13, 2021 | ||
Time: | 2:30 – 3:20 p.m. Eastern Time (ET) | ||
Panel title: | COVID-19 Vaccines – Staying Ahead of the Curve | ||
Novavax participant: | Vivek Shinde, M.D., M.P.H., Vice President, Clinical Development More on Marylandian
| ||
This event is open to Goldman Sachs clients. |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
More on Marylandian
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
- The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
- PUBLIC NOTICE UPDATE: Maryland Agencies to Treat Potomac River for Black Fly Control on June 30
- Maryland: Urban Agriculture Advisory Committee Meeting Notice
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
[email protected]
Solebury Trout
Jennifer Porcelli | 646-378-2962
[email protected]
Media
Laura Keenan | 410-419-5755
Amy Speak | 617-420-2461
[email protected]
SOURCE Novavax, Inc.
Related Links
http://www.novavax.com
Filed Under: Business
0 Comments
Latest on Marylandian
- Byrd Davis Alden & Henrichson Launches Independence Day Safe Ride Initiative with 500 Free Uber Credits
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
- INFINITI HR Expands Business Insurance Solutions: Coverage in Cyber, EPLI, Workers' Compensation
- PUBLIC NOTICE Maryland Agencies to Treat Potomac River for Black Fly Control on June 27
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
- Endoacustica Europe Unveils iPhone 13 Pro Max Spy Phone—Pure Hardware, Zero Software Changes
- Suzanne Harp named Managing Director in Texas, USA
- $10 Million Acquisition of GXR World Sports Assets Energizes Global Launch of Sports.com Super App by Online Lottery-Sports Game Provider: Lottery.com
- Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
- Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
- $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
- VoodooSoft Unveils SiriusLLM: The World's First ChatGPT-Like AI Malware Detection Engine
- This Ain't Press. This Is Pressure — Star Command by RansomXX is Out Now
- An Exclusive VIP Reception Honoring Vocal Prodigy Alliana Lili Yang's Remarkable Achievements and Magazine Cover Spotlight
- Joyce Carol Oates Returns to Hard Case Crime With DOUBLE TROUBLE
- New AI Academy Helps Therapists Embrace Tech Without Losing Their Humanity
- Iacocca Institute and Stanton Chase Launch Strategic Partnership for Leadership Development
- IQSTEL Surges Toward $400M Run Rate with $101.5M in Revenue—Reinforces Billion-Dollar Vision Backed by Fintech, AI, and Cybersecurity